The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review

ISSN： 0171-5216

Source： Journal of Cancer Research and Clinical Oncology, Vol.130, Iss.1, 2004-01, pp. : 1-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A Review of Current and Future Treatment Options in Renal Cancer

By Vaishampayan U.

American Journal of Cancer, Vol. 2, Iss. 3, 2003-01 ,pp. : 201-210

Adis International

Access to resources Recommend Favorite

Dexrazoxane use in the prevention of anthracycline extravasation injury

By Hasinoff Brian B

Future Oncology, Vol. 2, Iss. 1, 2006-02 ,pp. : 15-20

Future Medicine

Access to resources Recommend Favorite

Role of Second-Line Systemic Treatment Post-Docetaxel in Metastatic Castrate Resistant Prostate Cancer- Current Strategies and Future Directions

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 11, Iss. 3, 2011-03 ,pp. : 296-306

Bentham Science Publishers

Access to resources Recommend Favorite

A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment

By Marcu Loredana

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 10, 2009-10 ,pp. : 1303-1314

Springer Publishing Company

Access to resources Recommend Favorite

Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism

By Cusack B. Gambliel H. Musser B. Hadjokas N. Shadle S. Charlier H. Olson R.

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 4, 2006-10 ,pp. : 517-526

Springer Publishing Company

Access to resources Recommend Favorite